Relationship of Cerebral Perfusion Pressure Variability to Sepsis-associated Encephalopathy
- Conditions
- Sepsis
- Interventions
- Other: no interventions
- Registration Number
- NCT02288715
- Lead Sponsor
- Kang Yan
- Brief Summary
The purpose of the study is to evaluate whether variability of CPP (cerebral perfusion pressure) is related to sepsis-associated encephalopathy and outcomes of patients with sepsis.
- Detailed Description
Encephalopathy is a common complication of sepsis, impaired cerebrovascular autoregulation (AR) in patients with sepsis is considered related to Sepsis-associated encephalopathy (SAE). As AR is important in stabilizing the cerebral perfusion pressure, whether greater variability of CPP is related to SAE and mortality or not remains unclear. We conduct this study to evaluate the relationship between them.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 110
- clinical symptoms of sepsis, severe sepsis and septic shock
- age over 18 years
- preexisting Neurological diseases
- traumatic brain injury
- intracranial infectious disease
- severe hepatic or renal dysfunction
- ICU discharge Within 72 hours
- pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description SAE no interventions patient who develop encephalopathy in the progress of sepsis non-SAE no interventions patient who do not develop encephalopathy in the progress of sepsis
- Primary Outcome Measures
Name Time Method relationship between cerebral perfusion pressure variability and sepsis-associated encephalopathy cerebral perfusion pressure is assessed up to 72 hours To estimate CPP noninvasively, we will monitor the middle cerebral artery flow velocity of patients with sepsis using transcranial Doppler ultrasound in the first 72h of their enrollment. Diagnosis of a SAE was performed using the confusion assessment method for ICU(CAM-ICU).
- Secondary Outcome Measures
Name Time Method Duration of mechanical ventilation All the participants will be followed up until discharge or death, assessed up to 24 months Time of hospital stay All the participants will be followed up until discharge or death, assessed up to 24 months 90-day mortality rate All the participants will be followed up until 90 days after their enrollment or death Time of ICU stay All the participants will be followed up until discharge or death, assessed up to 24 months 2-year quality of life of survivors All the participants will be followed up until 2 year after their enrollment or death EQ-5D will be used to evaluate quality of life of survivors
1-year mortality rate All the participants will be followed up until 1 year after their enrollment or death 2-year mortality rate All the participants will be followed up until 2 years after their enrollment or death 1-year quality of life of survivors All the participants will be followed up until 1 year after their enrollment or death EQ-5D will be used to evaluate quality of life of survivors
Trial Locations
- Locations (1)
Kang Yan
🇨🇳Chengdu, Sichuan, China